Navigation Links
CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery
Date:3/15/2012

HELSINKI, Finland, March 15, 2012 /PRNewswire/ -- CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce intraoperative bleeding and, therefore, the volume of donor blood products (e.g., fresh frozen plasma, platelets, and red blood cells) needed during complex cardiovascular surgical procedures such as aortic aneurysm surgery. The study will also aim to show that FCH is safe and well tolerated. The primary efficacy endpoint measurement will be the number of units of all allogeneic blood products transfused during the first 24 hours after administration of FCH or placebo. 

"Potentially life-threatening bleeding events can occur during cardiovascular surgery because the patient's fibrinogen levels are depleted, which delays clotting," said Dr. Niels Rahe-Meyer, Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator  of the study. "The REPLACE Phase III study will help determine if FCH treatment can safely reduce the number of transfusions needed during cardiovascular surgery. If this is the case, we will have a powerful new option for use in protecting cardiovascular surgery patients from potentially life-threatening bleeding and transfusion-associated adverse events and discomfort." 

Of the 12 million units of blood used in the United States each year, 15 percent are used in cardiovascular surgery. Studies have shown that blood transfusion during or after adult cardiac surgery is associated with increased long-term mortality.

"As a global leader in the development of plasma-derived and recombinant coagulation fact
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
2. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
3. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
4. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
5. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
6. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
7. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
8. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
9. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
10. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
11. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , Mar. 30, 2015 Research and ... the addition of the "Medical Device Studies: ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:4/1/2015)...  Egalet Corporation (Nasdaq: EGLT ) ("Egalet"), ... developing, manufacturing and marketing innovative pain treatments, today ... million aggregate principal amount of its convertible senior ... placement to qualified institutional buyers pursuant to Rule ... amended (the "Act"). Egalet also granted the initial ...
(Date:4/1/2015)... 1, 2015  Salix Pharmaceuticals, Ltd. ("Salix"), a ... (NYSE: VRX ) (TSX:VRX), today announced that ... aggregate principal amount of its 6.00% Senior Notes ... Notes ") pursuant to two redemptions. On May ... amount of the Notes, and on May 4, ...
Breaking Medicine Technology:Medical Device Studies: Clinical Evidence Seminar - London, UK, 13th, 14th of May 2015 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 2Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 3Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 4Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 5Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 6Egalet Announces Proposed $60 Million Offering of Convertible Senior Notes Due 2020 7Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 2Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 3
... OMAHA, Neb., March 14, 2011 Transgenomic, Inc. ... announced the completion of an expanded license with the ... at Lower Denaturing temperature PCR) technology. Previously, Transgenomic had ... mitochondrial DNA analysis. The new license expands the technology ...
... OrbusNeich today announced the launch of the ... Stent combines the proven stent design of its ... a delivery system with enhanced crossability and flexible ... Helix stent design, offering conformability and radial strength ...
Cached Medicine Technology:Transgenomic Expands COLD-PCR License 2Transgenomic Expands COLD-PCR License 3Transgenomic Expands COLD-PCR License 4OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent 2
(Date:4/1/2015)... Manitowoc, WI (PRWEB) April 01, 2015 Skin ... and can be cured if caught early. Forefront Dermatology and ... Midwest recognize this dangerous condition before it spreads so they ... on Saturday, April 11th from 8:30am - 12:30pm. , ... help people identify areas of concern, that could become cancerous,” ...
(Date:4/1/2015)... Columbus, OH (PRWEB) April 01, 2015 ... adults, is proud to announce the establishment of the ... The scholarship is made possible through the generous gift ... presented the gift on behalf of Medical Mutual to ... Bonnie Quist, Vice President of Advancement & Strategic Relations. ...
(Date:4/1/2015)... Pricing Healthcare has added facilities to ... coverage to a third of all US states. The ... and Iowa, and the first dedicated eye center in the country ... was also added. , In addition, the site reached a milestone ... in the platform continue to grow across the country. , 1. ...
(Date:4/1/2015)... NC (PRWEB) April 01, 2015 Patients ... option available to them, thanks to the FDA’s approval ... to read the full story on the Surviving ... made from a modified version of the bacteria that ... to give its manufacturer grant funding and other incentives ...
(Date:4/1/2015)... Oakville, Ontario (PRWEB) April 01, 2015 ... over IP solutions infrastructure, announced today its strategic ... bring hosted voice solutions to the businesses of ... a game changing cross-platform application that offers users ... communication and collaboration tools. The objective of ...
Breaking Medicine News(10 mins):Health News:Forefront Dermatology and Dermatology Associates of Wisconsin Offers Skin Cancer Screenings on April 11th 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 2Health News:Franklin University Receives Gift to Create the Greta J. Russell Medical Mutual of Ohio Scholarship 3Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:Orphan Drug Approval May Mean New Treatment Option for Mesothelioma, According to Surviving Mesothelioma 2Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 2Health News:Phybridge and SaskTel Team Up to Eliminate Network Barriers for IP Telephony and Unified Communications Migration 3
... of Healthcare , ... Lisle, IL (PRWEB) December 17, ... highly qualified nurse administrators, nurse leaders and nurse educators, Benedictine University,s ... Master of Science in Nursing (M.S.N.) program. In launching the program, ...
... climb a couple of flights of stairs rather than take ... on the way up, deciding how to treat the symptoms ... , Whether it,s appropriate to treat chest pain with ... revascularizationthat is, by restoring good blood flow to the heart ...
... ACEL ) today announced that it received ... Qualifications Panel has determined to delist the Company,s securities ... of business on Tuesday, January 6, 2009. The delisting ... $35 million market value of listed securities requirement and ...
... need to restore community blood supplyNEW YORK, Jan. 5 ... community to please donate blood today, in recognition of ... replenish the local blood supply that has fallen sharply over ... are now at the critical 3-day level, with distribution restrictions ...
... and BCBSA Target April 2009 Interoperability Showcase at ... WASHINGTON, Jan. 5 Four leading healthcare industry ... Centers for Medicare and Medicaid Services (CMS) on ... address real-time testing of the new X12 HIPAA ...
... study finds, , , MONDAY, Jan. 5 (HealthDay News) -- More ... thanks to medical advances. But the long-term facilities, such as ... ready for the additional challenges that come with treating patients ... think of a way to successfully provide care for people ...
Cached Medicine News:Health News:Benedictine University Launches New Online Program, Master of Science in Nursing 2Health News:Benedictine University Launches New Online Program, Master of Science in Nursing 3Health News:New appropriate use criteria guide treatment of patients with heart blockage 2Health News:New appropriate use criteria guide treatment of patients with heart blockage 3Health News:New appropriate use criteria guide treatment of patients with heart blockage 4Health News:Alfacell Announces Receipt of NASDAQ Panel Decision 2Health News:Alfacell Announces Receipt of NASDAQ Panel Decision 3Health News:Donate Blood Today -- Save Up to Three Lives 2Health News:Donate Blood Today -- Save Up to Three Lives 3Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 2Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 3Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 4Health News:Healthcare Organizations Launch Collaborative Initiative to Test HIPAA Transactions Against Proposed 5010 Standards 5Health News:Diabetes Epidemic Now Poses Challenges for Nursing Homes 2Health News:Diabetes Epidemic Now Poses Challenges for Nursing Homes 3
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated...
The Valve Mapper Steerocath-Dx has a unique "peanut" shaped tip. It is designed to conform to the anatomy during mapping procedures. Both 8F/8mm and 8F/6mm tips are available....
... The NAVI-STAR catheter is specifically designed ... system. Our precision EP deflectable NAVI-STAR catheter ... distal tip to indicate, in real time, ... while simultaneously collecting local electrogram information. The ...
... Tricuspid Mapping. Biosense Webster offers a complete ... in the atrium. The HALO XP 20-pole ... and mapping around the tricuspid annulus. The ... distal tip (on P15-FS/0 permit pacing in ...
Medicine Products: